This study by Kang and co-authors 1 investigates the effect of decreasing HeartMate II
(Thoratec Corporation, Pleasanton, Calif) left ventricular assist device (LVAD; Figure 1) …

Background Nonsurgical bleeding is a frequent complication of continuous-flow left
ventricular assist device (LVAD) support. Abnormal von Willebrand factor (vWF) metabolism …

Mounting evidence points to both arterial pulsatility and pump shear as factors that may be
responsible for the high incidence of nonsurgical bleeding events observed in patients with …

While left ventricular assist devices (LVADs) have evolved over the decades, bleeding
complications are still the Achilles' heel. It is well known that supraphysiologic shear stress …

Background Supraphysiologic shear stress from continuous-flow left ventricular assist
devices (LVADs) accelerates von Willebrand factor (vWF) degradation and predisposes …

The management of continuous-flow left ventricular assist devices (LVADs) continues to
evolve. Benefits of pulsatile versus nonpulsatile mechanical circulatory support remain an …

Background Continuous‐flow left ventricular assist devices (LVADs) produces
supraphysiologic shear stress that causes von Willebrand factor (VWF) degradation and a …

Left ventricular assist devices (LVAD) have become a wellestablished therapy for end-stage
heart failure. Usually, LVAD flows vary between 3.5–6 L/min, regardless of the pump type or …

Left ventricular assist devices (LVADs) have emerged as a mainstay, lifesaving treatment
option for patients with refractory heart failure, with 1-and 2-year actuarial survival rates of …

A best evidence topic in cardiac surgery was written according to a structured protocol. The
question addressed was whether there is an optimal antithrombotic management for …